Autolus Therapeutics plc (AUTL) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended European Commission approval of obecabtagene autoleucel, or obe-cel, for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The CHMP recommendation was based on the results of the FELIX study, an open-label, multi centre, single arm study in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Obe-cel is currently approved by the U.S. Food and Drug Administration, and authorized by the U.K. Medicines and Healthcare products Regulatory Agency.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.